文献速递妇科

高危完全性葡萄胎单剂量预防性放线菌素D联合清宫术对妊娠滋养细胞肿瘤的一级预防:一项长期回顾性队列研究

Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
PubMed 文献 · Gynecol Oncol · 2025-01-11

该回顾性队列研究纳入1996至2023年426例高危完全性葡萄胎患者,其中290例在清宫时接受单次放线菌素D预防性化疗,136例未接受。预防性化疗组葡萄胎后妊娠滋养细胞肿瘤发生率为19%,对照组为39.7%(P<0.001),相对风险降低52%(RR=0.48;95%CI:0.35-0.66),需治疗人数为5。作者认为单次放线菌素D(1.25 mg/m2)可能安全预防妊娠滋养细胞肿瘤发生并降低相关发病率。

要点

  • 高危完全性葡萄胎清宫时单次放线菌素D预防性化疗可降低葡萄胎后妊娠滋养细胞肿瘤发生率。
  • 预防性化疗组妊娠滋养细胞肿瘤发生率19%(55/290) vs 对照组39.7%(54/136),P<0.001。
  • 相对风险降低52%(RR=0.48;95%CI:0.35-0.66;P<0.001),需治疗人数为5。

核心结论

  • 高危完全性葡萄胎患者清宫时给予单次放线菌素D(1.25 mg/m2)预防性化疗可能安全预防葡萄胎后妊娠滋养细胞肿瘤发生并降低相关发病率。
  • 作者认为该预防方法可在任何滋养细胞疾病中心采用。

研究设计与样本

  • 回顾性队列研究,1996至2023年从1623例妊娠滋养细胞疾病患者中选取426例高危完全性葡萄胎。
  • 290例在清宫时接受单次放线菌素D预防性化疗(高危完全性葡萄胎预防性化疗组),136例具有相同危险因素但未接受预防性化疗(高危完全性葡萄胎对照组)。

主要发现

  • 预防性化疗组葡萄胎后妊娠滋养细胞肿瘤发生率为19%(55/290),对照组为39.7%(54/136),P<0.001。
  • 发生葡萄胎后妊娠滋养细胞肿瘤的相对风险降低52%(RR=0.48;95%CI:0.35-0.66;P<0.001),需治疗人数为5。
  • 预防性化疗组诊断时血清hCG水平较低(P=0.007),复发风险较低(P=0.001),子宫切除风险较低(P=0.04)。
  • 两组至妊娠滋养细胞肿瘤诊断时间(P=0.09)、一线化疗反应(P=0.50)和至缓解时间(P=0.72)无显著差异。

关键数值与推荐

  • 预防性化疗方案为清宫时单次静脉推注放线菌素D 1.25 mg/m2。

临床怎么用

  • 作者认为高危完全性葡萄胎患者清宫时给予单次放线菌素D(1.25 mg/m2)预防性化疗可在任何滋养细胞疾病中心采用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of actinomycin D (ActD) as prophylactic chemotherapy (P-chem) in patients with high-risk complete hydatidiform mole (Hr-CHM) on progression to gestational trophoblastic neoplasia (GTN). METHODS: From 1996 to 2023, 426 Hr-CHMs were selected in a cohort of 1623 patients with gestational trophoblastic disease (GTD). From 1996 to 2023, 290 patients with Hr-CHMs received a single bolus dose of Act-D at the time of uterine evacuation (Hr-CHM P-chem group); 136 with the same risk factors did not receive P-chem (Hr-CHM control group). The variables assessed in post-molar GTN were incidence and morbidity considering hCG serum level at diagnosis, relapse frequency, hysterectomy rates. RESULTS: Post-molar GTN was diagnosed in 19 % of the patients with Hr-CHM P-Chem (55/290) and in 39.7 % of the patients in the Hr-CHM control group (54/136) (P < 0.001). The relative risk of developing post-molar GTN decreased by 52 % (RR = 0.48; 95 % CI: 0.35-0.66; P < 0.001), with a number needed to treat (NNT) of 5. Patients in the P-chem group had a lower hCG serum level (P = 0.007), lower risk of recurrence (P = 0.001) and lower risk of hysterectomy (P = 0.04), with no effect on time to GTN diagnosis (P = 0.09), first line chemotherapy response (P = 0.50) and time to remission (P = 0.72). CONCLUSION: A single bolus dose of Act-D (1.25 mg/m2) given as P-chem during uterine evacuation in patients with Hr-CHM may safely prevent the incidence of post-molar GTN and reduce the morbidity associated with GTN. This prophylactic approach can be adopted at any trophoblastic disease center (TDC).

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Uberti EMH, de Freitas Medeiros LR, Cardoso RB, et al. Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study. Gynecol Oncol. 2025. PMID: 39799786. doi:10.1016/j.ygyno.2025.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。